ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,393,600 | -53.3% | 544,000 | -39.6% | 0.78% | -46.2% |
| Q2 2023 | $41,549,291 | -51.3% | 900,700 | -57.7% | 1.45% | -48.7% |
| Q1 2023 | $85,288,690 | -38.4% | 2,126,900 | -28.9% | 2.83% | -5.7% |
| Q4 2022 | $138,526,700 | +63.1% | 2,990,000 | +45.7% | 3.00% | +73.8% |
| Q3 2022 | $84,957,000 | -3.7% | 2,051,600 | +38.7% | 1.73% | -14.8% |
| Q2 2022 | $88,267,000 | +39.9% | 1,479,500 | +70.3% | 2.03% | +54.2% |
| Q1 2022 | $63,107,000 | +7.2% | 869,000 | +24.1% | 1.31% | +5.3% |
| Q4 2021 | $58,863,000 | +43.4% | 700,000 | +53.8% | 1.25% | +37.3% |
| Q3 2021 | $41,036,000 | – | 455,000 | – | 0.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |